Dupixent for Eczema & Asthma: How It Works, Results & Savings
Dupixent transformed eczema treatment when it launched in 2017 — the first targeted biologic to address the underlying immune driver of atopic dermatitis. For patients who have failed topical steroids, tacrolimus, and other treatments, Dupixent can be life-changing.
Save on Dupixent
Most patients with insurance pay $0 per month with the Dupixent MyWay savings card. Uninsured patients may qualify for patient assistance. Compare prices and options at Rx.com.
What Is Dupixent?
Dupixent is a human monoclonal antibody (IgG4 class) that targets the IL-4 receptor alpha subunit shared by the IL-4 and IL-13 signaling pathways. Both IL-4 and IL-13 are cytokines (signaling proteins) that drive type 2 inflammation — the immune pathway responsible for atopic dermatitis, allergic asthma, and nasal polyps.
Manufactured by Sanofi and Regeneron, it was the first biologic approved specifically for atopic dermatitis (2017) and has since received additional approvals.
What Does Dupixent Treat?
| Indication | Age | Notes |
|---|---|---|
| Moderate-to-severe atopic dermatitis (eczema) | 6 months+ | When topical therapies fail; can be used with or without topical steroids |
| Moderate-to-severe asthma (type 2) | 6 years+ | With eosinophilic or oral corticosteroid-dependent phenotype |
| Chronic rhinosinusitis with nasal polyps | Adults | Reduces polyp size; improves nasal obstruction and smell |
| Eosinophilic esophagitis (EoE) | 12 years+ | Reduces esophageal inflammation and difficulty swallowing |
| Prurigo nodularis | Adults | Reduces chronic nodular itching |
| Chronic spontaneous urticaria (CSU) | Adults; pending | In clinical trials; approval expected |
| Chronic obstructive pulmonary disease (COPD) | Adults | Recent FDA approval for COPD with type 2 inflammation |
How It Works
In atopic dermatitis, the IL-4/IL-13 pathway does two damaging things: it weakens the skin barrier (causing dryness and allowing allergens/irritants in) and it creates an overactive immune response that causes intense itching, redness, and inflammation.
Dupixent specifically intercepts these signals before they reach cells — effectively turning down the "volume" on this inflammatory pathway without broadly suppressing the immune system (unlike corticosteroids or cyclosporine).
What Results to Expect
Clinical trial results from the SOLO and LIBERTY trials:
- 36–38% of patients achieved clear or almost clear skin (IGA 0/1) at 16 weeks
- 44–51% achieved ≥75% reduction in eczema severity score (EASI-75)
- Itch reduction (worst itch score) began improving within the first week in many patients
- Benefits continue to improve with long-term treatment; many patients achieve near-complete clearance after 1 year
Side Effects
Dupixent is remarkably well-tolerated compared to systemic immunosuppressants:
- Injection site reactions — redness, pain, swelling at the injection site; most common in the first few weeks
- Conjunctivitis — a significant side effect (10–30% in eczema patients); eye redness, irritation; usually responds to lubricating eye drops or steroid eye drops
- Headache
- Eosinophilia — mild elevation in eosinophil counts (white blood cells); usually not clinically significant
- Oral herpes (cold sores) — slightly increased incidence
Cost and Savings Programs
💲 Most insured patients pay $0/month
The Dupixent MyWay copay card covers up to $13,000 per year in out-of-pocket costs for commercially insured patients — meaning most pay $0–$30/month. Uninsured and underinsured patients may qualify for Dupixent patient assistance through Sanofi, which can provide the medication free of charge based on income. Contact 1-844-DUPIXENT for assistance.
Frequently Asked Questions
How quickly does Dupixent work for eczema?
Many patients notice itch improvement within the first week of the loading dose. Visible skin improvement (redness, scaling, thickening) typically shows meaningful progress at 4–8 weeks, with continued improvement for months. Many patients do not see the full benefit until 6–12 months of continuous treatment. Do not judge Dupixent by the first month alone.
Can Dupixent be used with topical steroids?
Yes — Dupixent is often used with topical corticosteroids (TCS) for faster clearance of active flares. Many patients use topical steroids to address breakthrough flares while on Dupixent maintenance. Over time, most patients reduce their TCS use significantly as Dupixent controls the underlying disease. Some patients ultimately use no steroids at all.
Does Dupixent suppress the immune system?
No, not in the broad sense. Unlike cyclosporine, methotrexate, or steroids — which suppress the entire immune system — Dupixent selectively targets the IL-4/IL-13 pathway (type 2 inflammation). It does not increase the risk of serious bacterial or viral infections that broad immunosuppressants do. This targeted approach is a major advantage over older systemic treatments for eczema.
What if my insurance does not cover Dupixent?
If you are uninsured or insurance denies coverage, contact Sanofi's Dupixent MyWay at 1-844-387-4936. Income-based patient assistance programs can provide Dupixent at no cost. Prior authorization denials can be appealed — your dermatologist's office can help document medical necessity. Patient advocacy groups can also assist with appeals.
How is Dupixent injected?
Dupixent comes in a pre-filled syringe or autoinjector pen. It is injected subcutaneously (under the skin) in the abdomen, thigh, or upper arm. The loading dose for eczema is two injections (600 mg total) at different sites on the same day, then one injection (300 mg) every two weeks. After your first dose in a clinical setting, self-injection at home is standard.
Check Dupixent Savings Options
Most insured patients pay $0/month with manufacturer savings cards. See your options at Rx.com.